Success Metrics

Clinical Success Rate
63.6%

Based on 7 completed trials

Completion Rate
64%(7/11)
Active Trials
1(8%)
Results Posted
157%(11 trials)
Terminated
4(31%)

Phase Distribution

Ph phase_2
2
15%
Ph phase_3
9
69%

Phase Distribution

0

Early Stage

2

Mid Stage

9

Late Stage

Phase Distribution11 total trials
Phase 2Efficacy & side effects
2(18.2%)
Phase 3Large-scale testing
9(81.8%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

63.6%

7 of 11 finished

Non-Completion Rate

36.4%

4 ended early

Currently Active

1

trials recruiting

Total Trials

13

all time

Status Distribution
Active(2)
Completed(7)
Terminated(4)

Detailed Status

Completed7
Terminated4
Recruiting1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
13
Active
1
Success Rate
63.6%
Most Advanced
Phase 3

Trials by Phase

Phase 22 (18.2%)
Phase 39 (81.8%)

Trials by Status

recruiting18%
terminated431%
not_yet_recruiting18%
completed754%

Recent Activity

Clinical Trials (13)

Showing 13 of 13 trials
NCT06997055

ROLL'YN-UST: an Observational Study in Patients Treated by Steqeyma®, an Ustekinumab Biosimilar

Recruiting
NCT03981744Phase 3

A Study of Ustekinumab in Participants With Active Polymyositis and Dermatomyositis Who Have Not Adequately Responded to One or More Standard-of-care Treatments

Terminated
NCT03517722Phase 3

A Study of Ustekinumab in Participants With Active Systemic Lupus Erythematosus

Terminated
NCT02438787Phase 3

A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF(Alpha) Refractory Participants With Active Radiographic Axial Spondyloarthritis

Terminated
NCT03464136Phase 3

Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year

Completed
NCT02437162Phase 3

A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNFα Naive Participants With Active Radiographic Axial Spondyloarthritis

Terminated
NCT06786507

A Direct Head-to-head Comparison of Ustekinumab with Infliximab for the Treatment of Ulcerative Colitis

Not Yet Recruiting
NCT02698475Phase 3

An Efficacy, Safety, and Pharmacokinetics Study of Subcutaneously Administered Ustekinumab in the Treatment of Moderate to Severe Chronic Plaque Psoriasis in Pediatric Participants Greater Than or Equal to 6 to Less Than 12 Years of Age

Completed
NCT01550744Phase 3

A Study of Ustekinumab to Evaluate a "Subject-tailored" Maintenance Dosing Approach in Subjects With Moderate-to-Severe Plaque Psoriasis

Completed
NCT01389973Phase 2

A Study of Efficacy and Safety of Ustekinumab in Patients With Primary Biliary Cirrhosis (PBC) Who Had an Inadequate Response to Ursodeoxycholic Acid

Completed
NCT01009086Phase 3

A Study of the Safety and Effectiveness of Ustekinumab in Patients With Psoriatic Arthritis

Completed
NCT01077362Phase 3

A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents

Completed
NCT00265122Phase 2

A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Participants With Crohn's Disease

Completed

All 13 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
13